Polysaccharides from Chinese herbal medicine: a review on the hepatoprotective and molecular mechanism

Abstract

Polysaccharides, predominantly extracted from traditional Chinese medicinal herbs such as Lycium barbarum, Angelica sinensis, Astragalus membranaceus, Dendrobium officinale, Ganoderma lucidum, and Poria cocos, represent principal bioactive constituents extensively utilized in Chinese medicine. These compounds have demonstrated significant anti-inflammatory capabilities, especially anti-liver injury activities, while exhibiting minimal adverse effects. This review summarized recent studies to elucidate the hepatoprotective efficacy and underlying molecular mechanisms of these herbal polysaccharides. It underscored the role of these polysaccharides in regulating hepatic function, enhancing immunological responses, and improving antioxidant capacities, thus contributing to the attenuation of hepatocyte apoptosis and liver protection. Analyses of molecular pathways in these studies revealed the intricate and indispensable functions of traditional Chinese herbal polysaccharides in liver injury management. Therefore, this review provides a thorough examination of the hepatoprotective attributes and molecular mechanisms of these medicinal polysaccharides, thereby offering valuable insights for the advancement of polysaccharide-based therapeutic research and their potential clinical applications in liver disease treatment.

Keywords

Polysaccharides / Hepatoprotective / Chinese herbal medicine / Mechanism

References

[1] Hernández-Aquino E, Muriel P. Beneficial effects of naringenin in liver diseases: molecular mechanisms[J]. World J Gastroenterol, 2018, 24(16): 1679-1707.

[2] Li YW, Ly YR, Nian MZ, et al. Therapeutic potential and mechanism of Chinese herbal medicines in treating fibrotic liver disease[J]. Chin J Nat Med, 2023, 21(9): 643-657.

[3] Tornai I. Role of environmental factors in the etiology of hepatocellular carcinoma[J]. Orv Hetil, 2010, 151(28): 1132-1136.

[4] Byass P. The global burden of liver disease: a challenge for methods and for public health[J]. BMC Med, 2014, 12: 159.

[5] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60(6): 2099-2108.

[6] Li J, Guo C, Wu J. Fucoidan: biological activity in liver diseases[J]. Am J Chin Med, 2020, 48(7): 1617-1632.

[7] Wu L, Gao Y, Su Y, et al. Probiotics with anti-type 2 diabetes mellitus properties: targets of polysaccharides from traditional Chinese medicine[J]. Chin J Nat Med, 2022, 20(9): 641-655.

[8] Corrie L, Gulati M, Awasthi A, et al. Harnessing the dual role of polysaccharides in treating gastrointestinal diseases: as therapeutics and polymers for drug delivery[J]. Chem Biol Interact, 2022, 368: 110238.

[9] Kalita P, Ahmed AB, Sen S, et al. A comprehensive review on polysaccharides with hypolipidemic activity: occurrence, chemistry and molecular mechanism[J]. Int J Biol Macromol, 2022, 206: 681-698.

[10] Liu Y, Huang G. Extraction and derivatisation of active polysaccharides[J]. J Enzyme Inhib Med Chem, 2019, 34(1): 1690-1696.

[11] Li X, Rao Z, Xie Z, et al. Isolation, structure and bioactivity of polysaccharides from Atractylodes macrocephala: a review[J]. J Ethnopharmacol, 2022, 296: 115506.

[12] Zeng P, Li J, Chen Y, et al. The structures and biological functions of polysaccharides from traditional Chinese herbs[J]. Prog Mol Biol Transl Sci, 2019, 163: 423-444.

[13] Li N, Yu X, Yu QH, et al. Research progress on stability of polysaccharides in traditional Chinese medicine[J]. Chin J Chin Mater Med, 2019, 44(22): 4793-4799.

[14] Chen X, Liu M, Tang J, et al. Research progress on the therapeutic effect of polysaccharides on non-alcoholic fatty liver disease through the regulation of the gut-liver axis[J]. Int J Mol Sci, 2022, 23(19): 11710.

[15] Staufer K, Huber SU, Strebinger G, et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease[J]. J Hepatol, 2022, 77(4): 918-930.

[16] Meghana P, Jain RSK, Prashanth N, et al. Artabotrys odoratissimus bark extract restores ethanol induced redox imbalance and toxicity in hepatocytes and in vivo model[J]. Appl Biochem Biotechnol, 2023, 195(5): 3366-3383.

[17] Hung HY, Hung WL, Shih CL, et al. Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis[J]. Ann Med, 2022, 54(1): 108-120.

[18] Amir M, Ahmad W, Sarafroz M, et al. Hepatoprotective effect of a polyherbal formulation (Aab-e-murawaqain) against CCl₄ induced liver toxicity in Wistar albino rat model by suppressing proinflammatory cytokines [J]. S Afr J Bot, 2022, 151: 75-81.

[19] Xu J, Wang R, Liu J, et al. Determination of monosaccharides in Lycium barbarum fruit polysaccharide by an efficient UHPLC-QTRAP-MS/MS method[J]. Phytochem Anal, 2021, 32(5): 785-793.

[20] Wei J, Zhang L, Liu J, et al. Protective effect of Lycium barbarum polysaccharide on ethanol-induced injury in human hepatocyte and its mechanism[J]. J Food Biochem, 2020, 44(10): e13412.

[21] Wang H, Li Y, Liu J, et al. Hepatoprotective effect of crude polysaccharide isolated from Lycium barbarum L. against alcohol-induced oxidative damage involves Nrf2 signaling[J]. Food Sci Nutr, 2020, 8(12): 6528-6538.

[22] Li D, Sun L, Yang Y, et al. Preventive and therapeutic effects of pigment and polysaccharides in Lycium barbarum on alcohol-induced fatty liver disease in mice[J]. CYTA J Food, 2018, 16(1): 938-949.

[23] Wang F, Tipoe GL, Yang C, et al. Lycium barbarum polysaccharide supplementation improves alcoholic liver injury in female mice by inhibiting stearoyl-CoA desaturase 1[J]. Mol Nutr Food Res, 2018, 62(13): e1800144.

[24] Yan Y, Wu W, Lu L, et al. Study on the synergistic protective effect of Lycium barbarum L. polysaccharides and zinc sulfate on chronic alcoholic liver injury in rats[J]. Food Sci Nutr, 2019, 7(11): 3435-3442.

[25] Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922.

[26] Bae UJ, Park EO, Park J, et al. Gypenoside UL4-rich Gynostemma pentaphyllum extract exerts a hepatoprotective effect on diet-induced nonalcoholic fatty liver disease[J]. Am J Chin Med, 2018, 46(6): 1315-1332.

[27] Xiao J, Wang F, Liong EC, et al. Lycium barbarum polysaccharides improve hepatic injury through NFkappa-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model[J]. Int J Biol Macromol, 2018, 120: 1480-1489.

[28] Gao LL, Ma JM, Fan YN, et al. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation[J]. Int J Biol Macromol, 2021, 183: 1379-1392.

[29] Liu ZC, Yu WW, Zhou HC, et al. Lycium barbarum polysaccharides ameliorate LPS-induced inflammation of RAW264.7 cells and modify the behavioral score of peritonitis mice[J]. J Food Biochem, 2021, 45(10): e13889.

[30] Gao LL, Li YX, Ma JM, et al. Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial[J]. Trials, 2021, 22(1): 566.

[31] Ding Y, Yan Y, Chen D, et al. Modulating effects of polysaccharides from the fruits of Lycium barbarum on the immune response and gut microbiota in cyclophosphamide-treated mice[J]. Food Funct, 2019, 10(6): 3671-3683.

[32] Liu RJ, He YJ, Liu H, et al. Protective effect of Lycium barbarum polysaccharide on di-(2-ethylhexyl) phthalate-induced toxicity in rat liver[J]. Environ Sci Pollut Res Int, 2021, 28(18): 23501-23509.

[33] Gan F, Liu Q, Liu Y, et al. Lycium barbarum polysaccharides improve CCl₄-induced liver fibrosis, inflammatory response and TLRs/NF-kappa B signaling pathway expression in wistar rats[J]. Life Sci, 2018, 192: 205-212.

[34] Chiang YY, Chao JCJ. Olive oil combined with Lycium barbarum polysaccharides attenuates liver apoptosis and inflammation induced by carbon tetrachloride in rats[J]. J Funct Foods, 2018, 48: 329-336.

[35] Sun X, Lv Y, Huang L, et al. Pro-inflammatory cytokines serve as communicating molecules between the liver and brain for hepatic encephalopathy pathogenesis and Lycium barbarum polysaccharides protection[J]. J Ethnopharmacol, 2020, 248: 112357.

[36] Shi S, Lan X, Feng J, et al. Hydrogel loading 2D montmorillonite exfoliated by anti-inflammatory Lycium barbarum L. polysaccharides for advanced wound dressing[J]. Int J Biol Macromol, 2022, 209: 50-58.

[37] Zou YF, Li CY, Fu YP, et al. The comparison of preliminary structure and intestinal anti-inflammatory and anti-oxidative activities of polysaccharides from different root parts of Angelica sinensis (Oliv.) Diels[J]. J Ethnopharmacol, 2022, 295: 115446.

[38] Nai J, Zhang C, Shao H, et al. Extraction, structure, pharmacological activities and drug carrier applications of Angelica sinensis polysaccharide[J]. Int J Biol Macromol, 2021, 183: 2337-2353.

[39] Zeng D, Wang Y, Chen Y, et al. Angelica polysaccharide antagonizes 5-FU-induced oxidative stress injury to reduce apoptosis in the liver through Nrf2 pathway[J]. Front Oncol, 2021, 11: 720620.

[40] Li C, Liu S, Zheng J, et al. Angelica sinensis polysaccharide (ASP) attenuates diosbulbin-B (DB)-induced hepatotoxicity through activating the MEK/ERK pathway[J]. Bioengineered, 2021, 12(1): 3516-3524.

[41] Zhang J, Hu C, Li X, et al. Protective effect of dihydrokaempferol on acetaminophen-induced liver injury by activating the SIRT1 pathway[J]. Am J Chin Med, 2021, 49(3): 705-718.

[42] Cao P, Sun J, Sullivan MA, et al. Angelica sinensis polysaccharide protects against acetaminophen-induced acute liver injury and cell death by suppressing oxidative stress and hepatic apoptosis in vivo and in vitro[J]. Int J Biol Macromol, 2018, 111: 1133-1139.

[43] He Z, Guo T, Cui Z, et al. New understanding of Angelica sinensis polysaccharide improving fatty liver: the dual inhibition of lipid synthesis and CD36-mediated lipid uptake and the regulation of alcohol metabolism[J]. Int J Biol Macromol, 2022, 207: 813-825.

[44] Wang K, Xu J, Liu Y, et al. Self-assembled Angelica sinensis polysaccharide nanoparticles with an instinctive liver-targeting ability as a drug carrier for acute alcoholic liver damage protection[J]. Int J Pharm, 2020, 577: 118996.

[45] Zhang Y, He Z, Liu X, et al. Oral administration of Angelica sinensis polysaccharide protects against pancreatic islets failure in type 2 diabetic mice: pancreatic beta-cell apoptosis inhibition[J]. J Funct Foods, 2019, 54: 361-370.

[46] Liu W, Li Z, Feng C, et al. The structures of two polysaccharides from Angelica sinensis and their effects on hepatic insulin resistance through blocking RAGE[J]. Carbohydr Polym, 2022, 280: 119001.

[47] Wang K, Wang J, Song M, et al. Angelica sinensis polysaccharide attenuates CCl₄-induced liver fibrosis via the IL-22/STAT3 pathway[J]. Int J Biol Macromol, 2020, 162: 273-283.

[48] Liu X, Wu Z, Guo C, et al. Hypoxia responsive nano-drug delivery system based on Angelica polysaccharide for liver cancer therapy[J]. Drug Deliv, 2022, 29(1): 138-148.

[49] Zhang Y, Cui Z, Mei H, et al. Angelica sinensis polysaccharide nanoparticles as a targeted drug delivery system for enhanced therapy of liver cancer[J]. Carbohydr Polym, 2019, 219: 143-154.

[50] Wang K, Wu J, Xu J, et al. Correction of anemia in chronic kidney disease with Angelica sinensis polysaccharide via restoring EPO production and improving iron availability[J]. Front Pharmacol, 2018, 9: 803.

[51] Wang J, Jia J, Song L, et al. Extraction, structure, and pharmacological activities of Astragalus polysaccharides[J]. Appl Sci-Basel, 2019, 9: 122.

[52] Xie JH, Jin ML, Morris GA, et al. Advances on bioactive polysaccharides from medicinal plants[J]. Crit Rev Food Sci Nutr, 2016, 56: S60-S84.

[53] Buret AG. Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin[J]. Can J Vet Res, 2010, 74(1): 1-10.

[54] Abani S, Farzaneh N, Seifi H, et al. Comparison of the effects of tylosin and tilmicosin as a systemic treatment of dry Holstein cows[J]. Vet Res Forum, 2022, 13(4): 495-499.

[55] Farag MR, Elhady WM, Ahmed SYA, et al. Astragalus polysaccharides alleviate tilmicosin-induced toxicity in rats by inhibiting oxidative damage and modulating the expressions of HSP70, NF-κB and Nrf2/HO-1 pathway[J]. Res Vet Sci, 2019, 124: 137-148.

[56] Wang G, Dong J, Deng L. Overview of cantharidin and its analogues[J]. Curr Med Chem, 2018, 25(17): 2034-2044.

[57] Huang X, Tang W, Lin C, et al. Protective mechanism of Astragalus polysaccharides against cantharidin-induced liver injury determined in vivo by liquid chromatography/mass spectrometry metabolomics[J]. Basic Clin Pharmacol Toxicol, 2021, 129(1): 61-71.

[58] Zhou J, Zhang N, Zhao L, et al. Astragalus polysaccharides and saponins alleviate liver injury and regulate gut microbiota in alcohol liver disease mice[J]. Foods, 2021, 10(11): 2688.

[59] Hamid M, Liu D, Abdulrahim Y, et al. Inactivation of kupffer cells by selenizing Astragalus polysaccharides prevents CCl₄-induced hepatocellular necrosis in the male wistar rat[J]. Biol Trace Elem Res, 2017, 179(2): 226-236.

[60] Hamid M, Liu D, Abdulrahim Y, et al. Amelioration of CCl₄-induced liver injury in rats by selenizing Astragalus polysaccharides: role of proinflammatory cytokines, oxidative stress and hepatic stellate cells[J]. Res Vet Sci, 2017, 114: 202-211.

[61] Huang WH, Liao WR, Sun RX. Astragalus polysaccharide induces the apoptosis of human hepatocellular carcinoma cells by decreasing the expression of Notch1[J]. Int J Mol Med, 2016, 38(2): 551-557.

[62] Lai XY, Xia WB, Wei J, et al. Therapeutic effect of Astragalus polysaccharides on hepatocellular carcinoma H22-bearing mice[J]. Dose Response, 2017, 15(1): 1559325816685182.

[63] Yao T, Chen JM, Shen LE, et al. Astragalus polysaccharide alleviated hepatocyte senescence via autophagy pathway[J]. Kaohsiung J Med Sci, 2022, 38(5): 457-468.

[64] Kong SZ, Lin GS, Liu JJ, et al. Hepatoprotective effect of ultrafine powder of Dendrobium officinale against acetaminophen-induced liver injury in mice[J]. Food Sci Technol Res, 2018, 24(2): 339-346.

[65] Yuan Y, Zhang J, Liu X, et al. Tissue-specific transcriptome for Dendrobium officinale reveals genes involved in flavonoid biosynthesis[J]. Genomics, 2020, 112(2): 1781-1794.

[66] Wu F, Zhang Y, Liu W, et al. Comparison of torrefied and lyophilized Dendrobii officinalis Caulis (Tiepishihu) by Fourier transform infrared spectroscopy and two-dimensional correlation spectroscopy[J]. J Mol Struct, 2020, 1204: 127554.

[67] He L, Yan X, Liang J, et al. Comparison of different extraction methods for polysaccharides from Dendrobium officinale stem[J]. Carbohydr Polym, 2018, 198: 101-108.

[68] Lin G, Luo D, Liu J, et al. Hepatoprotective effect of polysaccharides isolated from Dendrobium officinale against acetaminophen-induced liver injury in mice via regulation of the Nrf2-keap1 signaling pathway[J]. Oxid Med Cell Longev, 2018, 2018: 6962439.

[69] Yang K, Zhan L, Lu T, et al. Dendrobium officinale polysaccharides protected against ethanol-induced acute liver injury in vivo and in vitro via the TLR4/NF-kappaB signaling pathway[J]. Cytokine, 2020, 130: 155058.

[70] Nie G, Zhang Y, Zhou Z, et al. Dynamic evaluation of the protective effect of Dendrobium officinale polysaccharide on acute alcoholic liver injury mice in vitro and in vivo by NIR fluorescence imaging[J]. Anal Bioanal Chem, 2021, 413(23): 5715-5724.

[71] Targher G, Corey KE, Byrne CD, et al. The complex link between NAFLD and type 2 diabetes mellitus: mechanisms and treatments[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(9): 599-612.

[72] Yang J, Chen H, Nie Q, et al. Dendrobium officinale polysaccharide ameliorates the liver metabolism disorders of type II diabetic rats[J]. Int J Biol Macromol, 2020, 164: 1939-1948.

[73] Liu Y, Yang L, Zhang Y, et al. Dendrobium officinale polysaccharide ameliorates diabetic hepatic glucose metabolism via glucagon-mediated signaling pathways and modifying liver-glycogen structure[J]. J Ethnopharmacol, 2020, 248: 112308.

[74] Miao H, Zhang Y, Huang Z, et al. Lonicera japonica attenuates carbon tetrachloride-induced liver fibrosis in mice: molecular mechanisms of action[J]. Am J Chin Med, 2019, 47(2): 351-367.

[75] Wang K, Yang X, Wu Z, et al. Dendrobium officinale polysaccharide protected CCl₄-induced liver fibrosis through intestinal homeostasis and the LPS-TLR4-NF-kappaB signaling pathway[J]. Front Pharmacol, 2020, 11: 240.

[76] Yun B, Ahn SH, Oh J, et al. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: a nationwide study[J]. Hepatol Res, 2022, 52(12): 975-984.

[77] Xing S, Zhang X, Ke H, et al. Physicochemical properties of polysaccharides from Dendrobium officinale by fractional precipitation and their preliminary antioxidant and anti-HepG2 cells activities in vitro[J]. Chem Cent J, 2018, 12(1): 100.

[78] Li L, Wang Y, Zhao L, et al. Sanhuang Xiexin Decoction ameliorates secondary liver injury in DSS-induced colitis involve regulating inflammation and bile acid metabolism[J]. J Ethnopharmacol, 2022, 299: 115682.

[79] Liang J, Chen S, Hu Y, et al. Protective roles and mechanisms of Dendrobium officinal polysaccharides on secondary liver injury in acute colitis[J]. Int J Biol Macromol, 2018, 107(Pt B): 2201-2210.

[80] Chu W, Wang P, Ma Z, et al. Ultrasonic treatment of Dendrobium officinale polysaccharide enhances antioxidant and anti-inflammatory activity in a mouse D-galactose-induced aging model[J]. Food Sci Nutr, 2022, 10(8): 2620-2630.

[81] Oluwafemi AB, Olamide OT, Adefunke AO, et al. Ganoderma lucidum from red mushroom attenuates formaldehyde-induced liver damage in experimental male rat model[J]. Biology (Basel), 2020, 9(10): 313.

[82] Luo H, Tan D, Peng B, et al. The pharmacological rationales and molecular mechanisms of Ganoderma lucidum polysaccharides for the therapeutic applications of multiple diseases[J]. Am J Chin Med, 2022, 50(1): 53-90.

[83] Lu J, He R, Sun P, et al. Molecular mechanisms of bioactive polysaccharides from Ganoderma lucidum (Lingzhi), a review[J]. Int J Biol Macromol, 2020, 150: 765-774.

[84] Hao YY, Cui WW, Gao HL, et al. Jinlida Granules ameliorate the high-fat-diet induced liver injury in mice by antagonising hepatocytes pyroptosis[J]. Pharm Biol, 2022, 60(1): 274-281.

[85] Liang Z, Yuan Z, Li G, et al. Hypolipidemic, antioxidant, and antiapoptotic effects of polysaccharides extracted from Reishi mushroom, Ganoderma lucidum (Leysser: Fr) Karst, in mice fed a high-fat diet[J]. J Med Food, 2018, 21(12): 1218-1227.

[86] Lv XC, Wu Q, Yuan YJ, et al. Organic chromium derived from the chelation of Ganoderma lucidum polysaccharide and chromium (III) alleviates metabolic syndromes and intestinal microbiota dysbiosis induced by high-fat and high-fructose diet[J]. Int J Biol Macromol, 2022, 219: 964-979.

[87] Pan R, Lou J, Wei L. Significant effects of Ganoderma lucidum polysaccharide on lipid metabolism in diabetes may be associated with the activation of the FAM3C-HSF1-CAM signaling pathway[J]. Exp Ther Med, 2021, 22(2): 820.

[88] Li HN, Li Zhao L, Zhou DY, et al. Ganoderma lucidum polysaccharides ameliorates hepatic steatosis and oxidative stress in db/db mice via targeting nuclear factor E 2 (erythroid-derived 2)-related factor-2/heme oxygenase-1 (HO-1) pathway[J]. Med Sci Monit, 2020, 26: e921905.

[89] Xu Y, Zhang X, Yan XH, et al. Characterization, hypolipidemic and antioxidant activities of degraded polysaccharides from Ganoderma lucidum[J]. Int J Biol Macromol, 2019, 135: 706-716.

[90] Susilo RJK, Winarni D, Husen SA, et al. Hepatoprotective effect of crude polysaccharides extracted from Ganoderma lucidum against carbon tetrachloride-induced liver injury in mice[J]. Vet World, 2019, 12(12): 1987-1991.

[91] Lee JW. Antihepatotoxic and antioxidant activities of polysaccharide obtained from cultured mycelia of Ganoderma lucidum[J]. Korean J Food Nutr, 2019, 32(5): 417-424.

[92] Chen YS, Chen QZ, Wang ZJ, et al. Anti-inflammatory and hepatoprotective effects of Ganoderma lucidum polysaccharides against carbon tetrachloride-induced liver injury in kunming mice[J]. Pharmacology, 2019, 103(3-4): 143-150.

[93] Chen Y, Chen Q. Anti-inflammatory and hepatoprotective effects of Ganoderma lucidum polysaccharides on carbon tetrachloride-induced acute liver injury in mice[J]. Food Sci, 2017, 38(17): 210-215.

[94] Peng H, Zhong L, Cheng L, et al. Ganoderma lucidum: current advancements of characteristic components and experimental progress in anti-liver fibrosis[J]. Front Pharmacol, 2022, 13: 1094405.

[95] Chen C, Chen J, Wang Y, et al. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-beta/Smad signaling[J]. Phytomedicine, 2023, 110: 154626.

[96] Yu Y, Qian LQ, Du N, et al. Ganoderma lucidum polysaccharide enhances radiosensitivity of hepatocellular carcinoma cell line HepG2 through Akt signaling pathway[J]. Exp Ther Med, 2017, 14(6): 5903-5907.

[97] Xia QH, Lu CT, Tong MQ, et al. Ganoderma lucidum polysaccharides enhance the abscopal effect of photothermal therapy in hepatoma-bearing mice through immunomodulatory, anti-proliferative, pro-apoptotic and anti-angiogenic[J]. Front Pharmacol, 2021, 12: 648708.

[98] Zhang Y, Feng Y, Wang W, et al. Characterization and hepatoprotections of Ganoderma lucidum polysaccharides against multiple organ dysfunction syndrome in mice[J]. Oxid Med Cell Longev, 2021, 2021: 9703682.

[99] Chen S, Guan X, Yong T, et al. Structural characterization and hepatoprotective activity of an acidic polysaccharide from Ganoderma lucidum[J]. Food Chem X, 2022, 13: 100204.

[100] Li XL, He YL, Zeng PJ, et al. Molecular basis for Poria cocos mushroom polysaccharide used as an antitumour drug in China[J]. J Cell Mol Med, 2019, 23(1): 4-20.

[101] Wang YF, Zhang M, Ruan D, et al. Chemical components and molecular mass of six polysaccharides isolated from the sclerotium of Poria cocos[J]. Carbohydr Res, 2004, 339(2): 327-334.

[102] Tian H, Liu Z, Pu Y, et al. Immunomodulatory effects exerted by Poria Cocos polysaccharides via TLR4/TRAF6/NF-kappa B signaling in vitro and in vivo[J]. Biomed Pharmacother, 2019, 112: 108709.

[103] Wu K, Fan JL, Huang XY, et al. Hepatoprotective effects exerted by Poria Cocos polysaccharides against acetaminophen-induced liver injury in mice[J]. Int J Biol Macromol, 2018, 114: 137-142.

[104] Wu K, Guo C, Yang B, et al. Antihepatotoxic benefits of Poria cocos polysaccharides on acetaminophen-lesioned livers in vivo and in vitro[J]. J Cell Biochem, 2019, 120(5): 7482-7488.

[105] Jiang YH, Zhang Y, Wang YY, et al. Extracts of Poria cocos polysaccharides improves alcoholic liver disease in mice via CYP2E1 and NF-kappaB inflammatory pathways[J]. Chin J Chin Mater Med, 2022, 47(1): 134-140.

[106] Jiang YH, Wang L, Chen WD, et al. Poria cocos polysaccharide prevents alcohol-induced hepatic injury and inflammation by repressing oxidative stress and gut leakiness[J]. Front Nutr, 2022, 9: 963598.

[107] Pu Y, Liu Z, Tian H, et al. The immunomodulatory effect of Poria cocos polysaccharides is mediated by the Ca²⁺/PKC/p38/NF-kappa B signaling pathway in macrophages[J]. Int Immunopharmacol, 2019, 72: 252-257.

[108] Ye H, Ma S, Qiu Z, et al. Poria cocos polysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis[J]. J Ethnopharmacol, 2022, 296: 115457-115457.

[109] Wang J, Zheng D, Huang F, et al. Theabrownin and Poria cocos polysaccharide improve lipid metabolism via modulation of bile acid and fatty acid metabolism[J]. Front Pharmacol, 2022, 13: 875549.

[110] Tan YY, Yue SR, Lu AP, et al. The improvement of nonalcoholic steatohepatitis by Poria cocos polysaccharides associated with gut microbiota and NF-κB/CCL3/CCR1 axis[J]. Phytomedicine, 2022, 103: 154208.

[111] Qin L, Huang D, Huang J, et al. Integrated analysis and finding reveal anti-liver cancer targets and mechanisms of pachyman (Poria cocos polysaccharides)[J]. Front Pharmacol, 2021, 12: 742349.

[112] Cheng Y, Xie Y, Ge JC, et al. Structural characterization and hepatoprotective activity of a galactoglucan from Poria cocos[J]. Carbohydr Polym, 2021, 263: 117979.

Funding

National Natural Science Foundation of China(81900532)

National Natural Science Foundation of China(81700523)

Central Guidance Local Science and Technology Development Project of Dalian City(YANG Yong)